Biogen names haemophilia spin-off Bioverativ
pharmafile | August 10, 2016 | News story | Manufacturing and Production, Research and Development, Sales and Marketing | Biogen, bioverativ
Biogen has announced that Bioverativ will be the name of the standalone spin-off of its haemophilia and other blood disorders business, which expects to launch in 2017.
Bioverativ will be a publicly-traded global biotech that will trade on the NASDAQ stock market under the symbol BIVV. The company will continue commercialisation of Eloctate and Alprolix, which are indicated for the treatment of haemophilia A and B, respectively. The pair generated combined revenues of $640 million for the 12 months to March 31 2016. Both of these treatments are under development in collaboration with Swedish biotech Sobi.
Bioverativ will continue to develop these two drugs, with studies exploring the potential benefits of Fc fusion technology on long-term joint health, immunogenicity and immune tolerance induction in haemophilia patients who develop inhibitors.
Furthermore, the spin-off will focus on programs studying longer-acting factor therapies that utilise XTEN technology, a non-factor bi-specific antibody program to treat patients with haemophilia A and patients with inhibitors, and gene therapy programs for haemophilia A and B, as well as ongoing research relating to sickle cell disease.
John Cox, former executive VP of pharmaceutical operations and technology at Biogen and chief executive officer at Bioverativ, says: “As an independent and focused company, we believe that Bioverativ will be uniquely positioned to drive progress and advance the standard of care for people living with haemophilia. The new company’s name creates a clear connection to our Biogen heritage and biotech focus. It also conveys our commitment to actively working with patients, caregivers, health care professionals and advocacy leaders to create progress where patients need it most.”
Sean Murray
Related Content
Biogen’s high-dose Spinraza regimen receives European Commission approval for spinal muscular atrophy
Biogen’s Spinraza (nusinersen) has received approval from the European Commission (EC) as a new high-dose …
Biogen and Stoke report positive results for Dravet syndrome drug
Biogen and Stoke Therapeutics have shared encouraging new data for their experimental treatment, zorevunersen, which …
Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China
Eisai and Biogen have announced that Leqembi (lecanemab) has been launched in China as a …
